Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxalta's OBIZUR Gains EU Approval | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Baxalta’s OBIZUR Gains EU Approval

Treats bleeding episodes in acquired haemophilia A

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxalta was granted Marketing Authorization for OBIZUR [Antihaemophilic Factor (Recombinant), Porcine Sequence] by the European Commission for the treatment of bleeding episodes in adult patients with acquired haemophilia caused by antibodies to Factor VIII (FVIII), a rare and potentially life-threatening acute bleeding disorder.

OBIZUR is the first recombinant porcine sequence FVIII treatment available in Europe to treat acquired haemophilia A, and is designed to enable physicians to monitor treatment response by measuring FVIII activity levels in addition to clinical assessments.

The approval is supported by results of a global, multi-centre Phase II/III trial in which all patients treated with OBIZUR (28/28) showed a positive response (bleeding stopped or reduced) and clinical improvement, with FVIII activity levels at 20% or higher at 24 hours after initial infusion. Successful control (resolution) of the initial bleeding episode was observed in 86% (24/28) of all patients and in 94% (16/17) of those treated with OBIZUR as the first-line treatment.  

Acquired haemophilia A is a rare haemorrhagic disease in which autoantibodies against coagulation factor VIII, called FVIII-neutralizing antibodies (inhibitors), weaken the inherent coagulation system. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics